Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of October 2024. The document serves as a transaction notification regarding a purchase of company shares by a person closely associated with a Principal Director and Manager (PDMR).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a regulatory disclosure of a specific share transaction.
| Metric | Value |
|---|---|
| Transaction Type | Purchase |
| Instrument | Ordinary Shares (31 pence each) |
| Volume | 7,150 shares |
| Price per Share | £13.9365 |
| Transaction Date | October 30, 2024 |
| Exchange | London Stock Exchange (XLON) |
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It discloses a single transaction executed by Lady Susan Symonds, identified as a PCA of Sir Jonathan Symonds (Non-Executive Chair).
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. The document is limited to the statutory notification of the share purchase.
Investor Verification Points
- Verify the total shareholding of Lady Susan Symonds and Sir Jonathan Symonds following this transaction.
- Confirm the market price of GSK plc ordinary shares on October 30, 2024, to contextualize the £13.9365 purchase price.
- Review subsequent filings to determine if this transaction is part of a larger trading pattern by the Non-Executive Chair's associates.